A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
What is the purpose of this trial?
This study is designed to evaluate the efficacy and safety of intravenous Lucassin® (terlipressin) versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in subjects receiving standard of care albumin therapy.
- 18 Years and older
- September 2010
- Last Updated:
- March 12, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT01143246